ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...
Researchers found better detection, treatment and decreased smoking have been immensely helpful in reducing deaths due to ...
The "In Situ Hybridization Market Report by Product, Technique, Application, End User, Countries and Company Analysis ...
According to the American Cancer Society, more than 2 million new cancer cases are estimated to have been diagnosed in the ...
ImmunityBio’s Anktiva receives Saudi FDA approval for non-muscle invasive bladder cancer with carcinoma in-situ: Culver City, California Friday, January 16, 2026, 15:00 Hrs [IST ...
Armistice Capital acquired more shares of ImmunityBio as EMA recommended ANKTIVA approval and Q3 2025 product revenue surged ...
The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with Bacillus ...
Health and Me on MSN
Anktiva approved in Saudi Arabia as world’s first lung cancer therapy — all you need to know
Saudi Arabia approves Anktiva, an IL-15 immunotherapy, for bladder and lung cancer, marking its first regulatory clearance ...
Professor Zhaohui Tang and Associate Professor Zhilin Liu from the team of Professor Xuesi Chen at the Changchun Institute of ...
Professor Zhaohui Tang and Associate Professor Zhilin Liu from the team of Professor Xuesi Chen at the Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, developed ...
A new cancer therapy wakes up immune cells inside tumors and turns them against cancer.
An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback